Page last updated: 2024-11-04

vorinostat and Tachycardia, Ventricular

vorinostat has been researched along with Tachycardia, Ventricular in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Tachycardia, Ventricular: An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).

Research Excerpts

ExcerptRelevanceReference
"Vorinostat is a histone deacetylase inhibitor used in the treatment of recurrent or persistent cases of cutaneous T-cell lymphoma (CTCL)."4.88QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. ( Lynch, DR; Newby, LK; Washam, JB, 2012)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lynch, DR1
Washam, JB1
Newby, LK1

Reviews

1 review available for vorinostat and Tachycardia, Ventricular

ArticleYear
QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature.
    Cardiology journal, 2012, Volume: 19, Issue:4

    Topics: Antineoplastic Agents; Doxepin; Electrocardiography; Histone Deacetylase Inhibitors; Humans; Hydroxa

2012